KRAS and lung carcinoma: Therefore, in the present study, we evaluated the effectiveness of a pre-selected small-molecule PERK inhibitor on human lung carcinoma epithelial cells (A549)—a representative NSCLC cell line with mutations in the KRAS gene [37].